
GBI Research, the leading business intelligence provider, has released its latest research "Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth". The report focuses on the current scenario of orally administered drugs. Key segment of orally administered drugs which are covered in the report include small molecules, proteins, peptides and vaccines. The oral drug delivery market is forecast to show increase in the forecast period (2010-2017) due to increase in demand for innovative oral drugs. The report analyses marketed oral drugs based on molecule type and indication. Pipeline drugs by molecule type are discussed in detail. The report analyses different types of nano-technology which will decide the future of orally administered drugs. Key drug delivery companies are profiled with their proprietary technologies, pipeline molecules and deals. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.